Glaukos (GKOS)
(Delayed Data from NYSE)
$113.91 USD
-0.05 (-0.04%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $113.96 +0.05 (0.04%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
GKOS 113.91 -0.05(-0.04%)
Will GKOS be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for GKOS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GKOS
Why Is Waters (WAT) Down 5.1% Since Last Earnings Report?
Glaukos (GKOS) Gains 40.4% YTD: What's Driving the Rally?
GKOS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
Glaukos (GKOS) Reaches 52-Week High: What's Aiding the Stock?
Glaukos (GKOS) Q1 Earnings Miss Estimates, Revenues Up Y/Y
Other News for GKOS
Glaukos Governance and Compensation Strategy Evolves
Glaukos price target raised by $20 at Stifel, here's why
Glaukos Reaches Analyst Target Price
Glaukos price target raised by $10 at Wells Fargo, here's why
Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Glaukos (GKOS) and Arcus Biosciences (RCUS)